Prognosis of heart failure treated with digoxin or with ivabradine: A cohort study in the community.

Background: Resting heart rate (HR) reduction with ivabradine (IVA) improves outcomes of patients with heart failure and reduced ejection fraction (HFrEF). Nevertheless, the best option to slow HR in patients with HFrEF treated with beta-blockers and a HR >70 bpm is unsettled.

Aims: To evaluate whether, in patients with HFrEF, commencing therapy with digoxin (CT-DIG) is associated to a worse prognosis than commencing treatment with ivabradine (CT-IVA).

Prognosis of heart failure with preserved ejection fraction treated with β-blockers: A propensity matched study in the community.

Background: The effect of treatment with β-blockers on the prognosis of patients newly diagnosed with heart failure with preserved ejection fraction (HFpEF) is unknown.

Objective: To analyze the relationship of commencing treatment with the β-blockers bisoprolol or carvedilol (CT-βB) with the prognosis of newly diagnosed HFpEF.

Methods: Prospective study over 10years on 2704 patients with HFpEF.